Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 3/2022

01-03-2022 | Obesity | Macrovascular Complications in Diabetes (R SHAH, Section Editor)

Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention

Authors: Eftitan Y. Akam, Akua A. Nuako, Afkera K. Daniel, Fatima Cody Stanford

Published in: Current Diabetes Reports | Issue 3/2022

Login to get access

Abstract

Purpose of Review

Cardiometabolic diseases are a leading cause of morbidity and mortality in the USA and disproportionately impact racial and ethnic minorities. Multiple factors contribute to this disparity including genetic and socioeconomic factors, the latter of which contributes to disparities both through systemic barriers such as healthcare access and by directly impacting metabolism through epigenetics and environment-related alterations in the gut microbiome. This review will discuss advances in medicine that can be used to identify, prognosticate, and treat cardiometabolic diseases, and how these may be used to address existing disparities.

Recent Findings

There is growing research aimed at identifying novel cardiometabolic disease targets and expanding the use of existing pharmacotherapies based on comorbidities. Advances in metabolomics and genomics can give insight into an individual’s unique biochemical profile, providing the means for earlier identification of disease and specific treatment targets. Moreover, developments in telehealth and related medical device technologies can expand access to underserved minority populations and improve control of chronic conditions such as diabetes and hypertension.

Summary

Precision medicine may be integral to bridging the racial gap in cardiometabolic disease outcomes. Developments in genomics, metabolomics, wearable medical devices, and telehealth can result in personalized treatments for patients that account for the socioeconomic and genetic factors that contribute to poor health outcomes in minorities. As research in this field rapidly progresses, special efforts must be made to ensure inclusion of racial and ethnic minority populations in clinical research and equal access to all treatment modalities.
Literature
1.
National Center for Health, S., Health, United States, in Health, United States, 2018. 2019, National Center for Health Statistics (US): Hyattsville (MD).
2.•
Virani, S.S., et al., Heart Disease and Stroke Statistics—2021 Update. Circulation, 2021. 143(8): p. e254-e743. This is a very comprehensive review of cardiovascular disease statistics, including cardiometabolic and lifestyle risk factors.
3.•
Singh, G.K., et al., Widening Socioeconomic and Racial Disparities in Cardiovascular Disease Mortality in the United States, 1969-2013. Int J MCH AIDS, 2015. 3(2): p. 106-18. In this paper, researchers used population data to estimate cardiovascular disease disparities over time and found significantly increasing disparities, caused in part by improvements in mortality for high socioecnomic and majority populations.
4.
Mazimba, S. and P.N. Peterson, JAHA spotlight on racial and ethnic disparities in cardiovascular disease. J Am Heart Assoc, 2021. 10(17): p. e023650.
5.
Mody P, et al. Most important articles on cardiovascular disease among racial and ethnic minorities. Circ Cardiovasc Qual Outcomes. 2012;5(4):e33-41.PubMed
6.
7.
Wang Y, Beydoun MA. The obesity epidemic in the United States–gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6–28.PubMed
8.
Hales, C.M., et al., Prevalence of obesity and severe obesity among adults: United States, 2017–2018., in NCHS Data Brief. 2020, National Center for Health Statistics: Hyattsville, MD.
9.
Sarwar N, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.PubMed
10.
Prevention, C.f.D.C.a., National Diabetes Statistics report, 2020. 2020, Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services: Atlanta, GA.
11.
12.
Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.PubMed
13.
Rich NE, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(2):198-210.e2.PubMed
14.
15.
Carroll, M.D. and C.D. Fryar, Total and high-density lipoprotein cholesterol in adults: United States, 2015–2018., N.C.f.H. Statistics, Editor. 2020, NCHS Data Brief: Hyattsville, MD.
16.
Havranek EP, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132(9):873–98.PubMed
17.
Soler-Botija C, Gálvez-Montón C, Bayés-Genís A. Epigenetic biomarkers in cardiovascular diseases. Front Genet. 2019;10:950.PubMedPubMedCentral
18.
Phillips, M.L., Gut reaction: environmental effects on the human microbiota, in Environ Health Perspect. 2009. p. A198–205.
19.
Moyer, V.A., Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2012. 157(5): p. 373–8.
20.
Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.PubMed
21.
Ussher JR, et al. The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J Am Coll Cardiol. 2016;68(25):2850–70.PubMed
22.
Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56–64.PubMedPubMedCentral
23.
Ganna, A., et al., Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease. PLoS Genet, 2014. 10(12): p. e1004801.
24.
Park, J.Y., et al., Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. PLoS One, 2015. 10(8): p. e0135228.
25.
Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124(10):4204–11.PubMedPubMedCentral
26.
Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(3):193–205.PubMed
27.
Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–248.PubMed
28.
Cheatham SW, et al. The efficacy of wearable activity tracking technology as part of a weight loss program: a systematic review. J Sports Med Phys Fitness. 2018;58(4):534–48.PubMed
29.
Lachausse RG. My student body: effects of an internet-based prevention program to decrease obesity among college students. J Am Coll Health. 2012;60(4):324–30.PubMed
30.
Sorgente, A., et al., Web-based interventions for weight loss or weight loss maintenance in overweight and obese people: a systematic review of systematic reviews. J Med Internet Res, 2017. 19(6): p. e229.
31.
Napolitano MA, et al. Using Facebook and text messaging to deliver a weight loss program to college students. Obesity (Silver Spring). 2013;21(1):25–31.
32.
Strelitz J, et al. Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and all-cause mortality: an observational analysis of the ADDITION-Europe trial. Diabetes Obes Metab. 2021;23(3):730–41.PubMed
33.
Sheard NF, et al. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the american diabetes association. Diabetes Care. 2004;27(9):2266–71.PubMed
34.
Vega-López S, et al. Interindividual variability and intra-individual reproducibility of glycemic index values for commercial white bread. Diabetes Care. 2007;30(6):1412–7.PubMed
35.
Vrolix R, Mensink RP. Variability of the glycemic response to single food products in healthy subjects. Contemp Clin Trials. 2010;31(1):5–11.PubMed
36.
Zeevi D, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163(5):1079–94.PubMed
37.
Qin J, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.PubMed
38.
Boursier J, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–75.PubMed
39.
Zhu L, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–9.PubMed
40.
Koeth RA, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.PubMedPubMedCentral
41.
42.
Gilbert JA, et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature. 2016;535(7610):94–103.PubMed
43.
Zhu W, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–24.PubMedPubMedCentral
44.
Tilg H, et al. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20(1):40–54.PubMed
45.
Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther. 2017;19(S3):S25-s37.PubMed
46.
Eiland L, Thangavelu T, Drincic A. Has technology improved diabetes management in relation to age, gender, and ethnicity? Curr Diab Rep. 2019;19(11):111.PubMed
47.
Honigberg MC, et al. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. JAMA Cardiology. 2020;5(10):1182–90.PubMedPubMedCentral
48.
Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res. 2018;2018:4020492–4020492.PubMedPubMedCentral
49.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.PubMed
50.
Mann JFE, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–48.PubMed
51.
Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403–13.PubMed
52.
Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–25.PubMed
53.
McGuire DK, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiology. 2021;6(2):148–58.PubMed
54.
Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.PubMed
55.
Zannad F, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–29.PubMed
56.
Yancy CW, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.PubMed
57.
Cooper, L.B., et al., Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. Journal of the American Heart Association, 2017. 6(12): p. e006540.
58.
Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29.PubMed
59.
Pitt, B., et al., Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med, 2021.
60.
Pitt B, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–63.PubMedPubMedCentral
61.
Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol. 2019;74(12):1594–607.PubMedPubMedCentral
62.
Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–26.PubMed
63.
Cinoku, I.I., C.P. Mavragani, and H.M. Moutsopoulos, Atherosclerosis: beyond the lipid storage hypothesis. The role of autoimmunity. Eur J Clin Invest, 2020. 50(2): p. e13195.
64.
Dregan A, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014;130(10):837–44.PubMed
65.
Murphy AJ, Febbraio MA. Immune-based therapies in cardiovascular and metabolic diseases: past, present and future. Nat Rev Immunol. 2021;21(10):669–79.PubMed
66.
Shaposhnik Z, et al. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res. 2009;50(4):623–9.PubMedPubMedCentral
67.
Nicholls SJ, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 Randomized Clinical Trial. JAMA. 2014;311(3):252–62.PubMed
68.
Wilensky RL, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14(10):1059–66.PubMedPubMedCentral
69.
White HD, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–11.PubMed
70.
Ridker PM, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–62.PubMed
71.
Chung ES, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–40.PubMed
72.
Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 2015;24(3):283–307.PubMed
73.
Bernstein LE, et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006;166(8):902–8.PubMedPubMedCentral
74.
Tardif JC, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9626):1761–8.PubMed
75.
Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.PubMed
76.
Levine GN, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082–115.PubMed
77.
Mega JL, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–30.PubMedPubMedCentral
78.
Klein MD, et al. Clinical utility of <i>CYP2C19</i> genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2019;39(4):647–52.PubMed
79.
Tada H, et al. Rare and deleterious mutations in ABCG5/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype. Circ J. 2019;83(9):1917–24.PubMed
80.
Tada H, et al. Sitosterolemia, hypercholesterolemia, and coronary artery disease. J Atheroscler Thromb. 2018;25(9):783–9.PubMedPubMedCentral
81.
Tada H, et al. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis. 2020;19(1):3.PubMedPubMedCentral
82.
Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018;71(1):1–7.PubMed
83.
FDA approves first treatment for weight management for people with certain rare genetic conditions. 2020.
84.
Akbari, P., et al., Sequencing of 640,000 exomes identifies <i>GPR75</i> variants associated with protection from obesity. Science, 2021. 373(6550): p. eabf8683.
85.
Hodatsu A, et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. Am J Physiol Heart Circ Physiol. 2014;307(11):H1594–604.PubMed
86.
Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–24.PubMedPubMedCentral
87.
Tada H, Kawashiri MA, Yamagishi M. Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. J Hum Genet. 2017;62(4):453–8.PubMed
88.
89.
Committee, P.E. Bariatric surgery procedures. 2021 [cited 2021 November 21].
90.
McCarty TR, Thompson CC. The current state of bariatric endoscopy. Dig Endosc. 2021;33(3):321–34.PubMed
91.
Coakley M, et al. Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials. J Womens Health (Larchmt). 2012;21(7):713–6.
92.
93.
Bentley AR, Callier S, Rotimi CN. Diversity and inclusion in genomic research: why the uneven progress? J Community Genet. 2017;8(4):255–66.PubMedPubMedCentral
94.
Kahn, J.M., et al., Strategies to improve diversity, equity, and inclusion in clinical trials. Cancer, 2021.
95.•
Clark, L.T., et al., Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. Current Problems in Cardiology, 2019. 44(5): p. 148-172. In this paper, the authors investigated barriers to participation in clinical trials in minority communities both through literatire review and direct interviews with stakeholers. They identified critical themes in barriers and proposed solutions for how to increase minority participation in clinical research.
Metadata
Title
Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention
Authors
Eftitan Y. Akam
Akua A. Nuako
Afkera K. Daniel
Fatima Cody Stanford
Publication date
01-03-2022
Publisher
Springer US
Keywords
Obesity
Obesity
Published in
Current Diabetes Reports / Issue 3/2022
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-022-01451-6

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits